The Supreme Court's ruling regarding challenges to generic drug deals "is a significant victory for American consumers, American taxpayers, and free markets," the FTC says, noting that the ruling against "pay-for-delay agreements" makes it clear that these deals are subject to antitrust scrutiny. As MarketWatch notes however, stocks have pretty much shrugged it off with Actavis (ACT -1%) and AbbVie (ABBV -0.8%) down a bit, Teva (TEVA +0.3%) acting like nothing happened, and Impax (IPXL -0.7%) down only fractionally.